NasdaqGS - Nasdaq Real Time Price USD

Vertex Pharmaceuticals Incorporated (VRTX)

455.45

-4.61

(-1.00%)

At close: June 13 at 4:00:00 PM EDT

455.45

0.00

(0.00%)

Pre-Market: 6:25:05 AM EDT

Vertex Pharmaceuticals (VRTX) Stock Moves -1.00%: What You Should Know

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $455.45, denoting a -1% move from the preceding trading day.

Zacks 2 days ago

VRTX
-1.00%
Vertex Presents New Data on the Benefits of ALYFTREK

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company shared new data at the 48th European Cystic Fibrosis Conference, revealing that ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) is linked with improved clinical outcomes and quality of life in cystic fibrosis (CF) patients. A pooled research found that sweat chloride (SwCl) levels […]

Insider Monkey 4 days ago

VRTX
-1.00%
1 Nasdaq 100 Stock for Long-Term Investors and 2 to Ignore

The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like profitability concerns, rising costs, or shifts in market trends.

StockStory 6 days ago

VRTX
-1.00%

MCHP

MNST
Vertex Pharmaceuticals (NasdaqGS:VRTX) Highlights Clinical Benefits Of ALYFTREK At Cystic Fibrosis Conference

Vertex Pharmaceuticals (NasdaqGS:VRTX) presented promising clinical data on their CFTR modulator ALYFTREK at the European Cystic Fibrosis Conference, showcasing improved outcomes for patients with reduced sweat chloride levels. These developments, highlighting both positive patient outcomes and important safety considerations, likely added weight to the company's 3.6% price increase over the past month. During the same period, the broader market experienced a rise of 1.8%, suggesting that...

Simply Wall St. 8 days ago

VRTX
-1.00%
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference

BOSTON, June 06, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s Euro

Business Wire 9 days ago

VRTX
-1.00%
Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report?

Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 9 days ago

APLS

VRTX
-1.00%
Cytokinetics (CYTK) Down 1.9% Since Last Earnings Report: Can It Rebound?

Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 10 days ago

CYTK

VRTX
-1.00%
Vertex (VRTX) Down 0.8% Since Last Earnings Report: Can It Rebound?

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 11 days ago

AGIO

VRTX
-1.00%
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks 11 days ago

VRTX
-1.00%
2 Top Stocks to Buy Right Now

Berkshire Hathaway remains an attractive investment despite its upcoming leadership change. Vertex Pharmaceuticals has room to grow in its core market and continues to innovate in new areas. Two great examples are Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) and Vertex Pharmaceuticals (NASDAQ: VRTX).

Motley Fool 15 days ago

VRTX
-1.00%
Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Biogen (NASDAQ:BIIB).

StockStory 17 days ago

BIIB

UTHR

VRTX
-1.00%
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment -- and that’s set to continue thanks to the company's innovation. The three major indexes slid in March and April as investors worried about the impact of President Donald Trump's import tariffs on the economy -- but in recent weeks, optimism about lower, more manageable tariff levels has grown. Trump struck a deal with the U.K. and has signed an initial agreement with China, signs that the impact of tariffs may be limited.

Motley Fool 19 days ago

VRTX
-1.00%
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Myriad Genetics (NASDAQ:MYGN) and its peers.

StockStory 20 days ago

MYGN

BMRN

UTHR
3 Top Growth Stocks to Buy in the Second Half of 2025

Amazon could hold up better than many expect if steep tariffs remain in place. Meta Platforms should benefit from multiple AI tailwinds. Vertex Pharmaceuticals has two new drugs on the market, with more potentially on the way.

Motley Fool 21 days ago

VRTX
-1.00%

META

AMZN
2 Monster Growth Stocks to Buy and Hold for 10 Years

Shopify should benefit from the switch to e-commerce thanks to its strong position and competitive edge. Vertex Pharmaceuticals' expanding lineup and deep pipeline can help it overcome recent headwinds. Despite recent market volatility, buying shares of top companies that can at least match average returns through 2035 -- or do much better -- is still worth it.

Motley Fool 22 days ago

SHOP

VRTX
-1.00%
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030

Vertex Pharmaceuticals should have big winners with pain drug Journavx and two promising pipeline candidates. Summit Therapeutics is poised for major success with its cancer immunotherapy, ivonescimab. People need healthcare products and services regardless of what's happening with the economy.

Motley Fool 26 days ago

VRTX
-1.00%

SMMT

IOVA
CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy?

CRISPR Therapeutics stock is down more than 80% from the peak it reached in 2021. The first drug from CRISPR Therapeutics launched early last year, but annualized sales are still less than $60 million. CRISPR Therapeutics recently reported promising early-stage clinical trial results for a cholesterol-reducing treatment.

Motley Fool 27 days ago

CRSP

VRTX
-1.00%
VRTX Q1 Earnings Call: New Product Launches and Pipeline Progress Amid Revenue Miss

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company’s full-year revenue guidance of $11.88 billion at the midpoint came in 0.9% below analysts’ estimates. Its non-GAAP profit of $4.06 per share was 5.4% below analysts’ consensus estimates.

StockStory 27 days ago

VRTX
-1.00%
The Top Corporate Board Directors

Who are the most influential directors at big publicly traded U.S. companies? The first annual Wall Street Journal ranking identifies 251 of them.

The Wall Street Journal 28 days ago

LMT

CVX

CAT
Warren Buffett Remains Optimistic About America. Here Are Top American Companies Worth Investing In.

Warren Buffett has guided Berkshire Hathaway through U.S. stock market investing for 59 years. Buffett’s investing has spanned all market environments. The top investor continues to believe in the future of American companies -- and their stock performance.

Motley Fool 29 days ago

CHWY

KO

AXP

Performance Overview

Return	VRTX	S&P 500 (^GSPC)
YTD	+13.10%	+1.62%
1-Year	-4.92%	+10.00%
3-Year	+85.60%	+59.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals (VRTX) Stock Moves -1.00%: What You Should Know

Vertex Presents New Data on the Benefits of ALYFTREK

1 Nasdaq 100 Stock for Long-Term Investors and 2 to Ignore

Vertex Pharmaceuticals (NasdaqGS:VRTX) Highlights Clinical Benefits Of ALYFTREK At Cystic Fibrosis Conference

Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference

Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report?

Cytokinetics (CYTK) Down 1.9% Since Last Earnings Report: Can It Rebound?

Vertex (VRTX) Down 0.8% Since Last Earnings Report: Can It Rebound?

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

2 Top Stocks to Buy Right Now

Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1

3 Top Growth Stocks to Buy in the Second Half of 2025

2 Monster Growth Stocks to Buy and Hold for 10 Years

Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030

CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy?

VRTX Q1 Earnings Call: New Product Launches and Pipeline Progress Amid Revenue Miss

The Top Corporate Board Directors

Warren Buffett Remains Optimistic About America. Here Are Top American Companies Worth Investing In.

Performance Overview